ANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 5,400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the sale, the chief executive officer owned 333,689 shares of the company’s stock, valued at $23,988,902.21. The trade was a 1.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, September 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $71.00, for a total value of $383,400.00.
• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.30, for a total value of $401,220.00.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP traded up $0.01 during trading on Friday, hitting $72.29. 333,921 shares of the company’s stock were exchanged, compared to its average volume of 382,196. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals, Inc. has a 52-week low of $69.58 and a 52-week high of $97.00. The business’s 50-day simple moving average is $73.71 and its 200 day simple moving average is $78.01. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 2.26 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter last year, the company earned $1.80 EPS. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.

Wall Street Analyst Weigh In

ANIP has been the topic of several recent analyst reports. Oppenheimer started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective on the stock. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective for the company. Finally, Canaccord Genuity Group cut their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $99.60.

Institutional Trading of ANI Pharmaceuticals

Hedge funds have recently modified their holdings of the company. KBC Group NV bought a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Versant Capital Management Inc grew its holdings in shares of ANI Pharmaceuticals by 103.3% in the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 217 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in ANI Pharmaceuticals in the second quarter worth $76,000. State of Wyoming bought a new stake in ANI Pharmaceuticals in the second quarter worth $86,000. Finally, GAMMA Investing LLC increased its position in ANI Pharmaceuticals by 13.4% in the third quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 211 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.